Agenda:
Day One: Tuesday 4 October 2005
08.00
Registration

08.50
BALLROOM
Chairman's Opening Welcome:
Biotech start-up strategies in retrospect and outlook
Dr Rudolf Gygax, Managing Director, Novartis Venture Fund, Novartis International
09.20-09.40
Keynote Presentation:
Identifying the Symmetry between the European and US Markets
Dennis Purcell, Managing Director, Perseus-Soros BioPharmaceutical Fund
09.40-10.25
Panel Discussion:
Global Investment Themes 2006 and Beyond
Chair:
Dr Jesper Zeuthen, Managing Director, BankInvest Biomedical Venture
Panelists:
Joël Besse, Senior Partner, Atlas Venture
Dr Andreas Wicki, CEO, HBM Partners
Dr Denise Pollard-Knight, Head of Nomura Phase4 Ventures, Nomura Phase4 Ventures
Dr Alexandra Goll, General Partner, Techno Venture Management (TVM)
10.25
Coffee Break
11.05-13.10
Small-Cap Listed Company Presentations
11.05
ROOM ZURICH:
Chair: Stan Yakatan
Katan Associates		 ROOM BASEL:
Chair: Dr Kai Bindseil,
BioTop		 ROOM BERN:
Chair: Dr Ivica Cerina,
NGN Capital
11.10
SyntheMed
Robert Hickey,
President & CEO 		Biophan Technologies
Michael Weiner,
Chief Executive Officer 		Cyberkinetics Neurotechnology Systems
Tim Surgenor, President & CEO
11.25
Favrille
Dr John Longnecker,
President & CEO 		Acrux
Dr Igor Gonda,
Managing Director & CEO 		Clearant
Alain Delongchamp,
Chief Executive Officer
11.40
XL Tech Group
Dr John Scott,
Chief Executive Officer		 YM Biosciences
David Allan,
Chairman & CEO		 Futura Medical
James Barder,
Chief Executive Officer
11.55
CogState
Dr Peter Bick,
Director & CEO 		Evolutec
Dr Mark Carnegie Brown,
Chief Executive Officer		 Novadaq Technologies
Dr Arun Menawat,
President & CEO
12.10
Generex Biotechnology
Dr Gerald Bernstein,
Vice President, Medical Affairs Director		 Amarin Corporation
Darren Cunningham,
Executive Vice President, Strategic Development		 Biotie Therapies
Dr Timo Veromaa,
President & CEO
12.25
BioPure Corporation
Zafaris Zafirelis,
President & CEO 		Plethora Solutions
Dr Steven Powell,
Chief Executive Officer 		 
12.40
Oncolytics Biotech
Dr Brad Thompson,
President & CEO 		BioMS Medical
Dr Kjell Stenberg,
Director		 Diamyd Medical
Anders Essen-Moller,
Chief Executive Officer
12.55
  Transgene
Philippe Archinard,
Chief Executive Officer		 Swiss Medica
Raghu Kilambi,
Chief Executive Officer
13.15
Lunch
14.15-16.20
Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies
14.15
ROOM ZURICH:
IMMUNOLOGY/ONCOLOGY
Chair: Christoph Schuler,
SWX Swiss Exchange		 ROOM BASEL:
THERAPEUTICS
Chair: Dr Denise Pollard-Knight,
Nomura Phase4 Ventures		 ROOM BERN:
THERAPEUTICS
Chair: Dr Hans A Küpper,
Global Life Science Ventures
14.20
immatics biotechnologies
Joerg Scheidle,
Managing Director & CFO 		DIREVO Biotech
Andreas Richter,
Chief Financial Officer 		Biovertis
Dr Erich Felber,
Chief Executive Officer
14.35
ImVisioN
Dr Martin Steiner,
Chief Executive Officer		 Necura Pharmaceuticals
Speaker tbc.
 ACE Biosciences
Ingelise Saunders,
Chief Executive Officer
14.50
Avidex
James Noble,
Chief Executive Officer 		Kuros Biosurgery
Didier Cowling,
President & CEO		 Bayhill Therapeutics
Dr Mark Schwartz,
President & CEO
15.05
Chroma Therapeutics
Ian Nicholson,
Chief Executive Officer 		Speedel
Konrad P Wirz,
Chief Financial Officer 		Neuro3d
Dr Bertrand Lehuu,
Vice President Business Development
15.20
Heidelberg Pharma
Dr Jan Schmidt-Brand,
Chief Executive Officer 		DeveloGen
Dr Guenther Karmann,
Chief Executive Officer		 Apoxis
Dr Jean-Pierre Rosat,
Chief Executive Officer
15.35
Austrianova
Thomas Fischer,
Chief Financial Officer
 Cellerix
Eduardo Bravo,
Chief Executive Officer
 Polyphor
Dr Jean-Pierre Obrecht,
Chief Executive Officer
15.50
ESBATech
Dominik Escher,
Chief Executive Officer 		Ablynx
Dr Simon Kerry,
Director Business Development 		PIERIS Proteolab
Dr Volker Lang,
Vice President Corporate Development
16.05
Santaris Pharma
Dr Keith McCullagh,
Chief Executive Officer 		Ingenium Pharmaceuticals
Michael Grau,
Chief Financial Officer 		Affibody
Torben Jørgensen,
Chief Executive Officer
16.20
Coffee Break
16.50
BALLROOM:
Welcome by Mayor of Zurich
Dr Elmar Ledergerber
16.55 - 17.15
Investing in Biotechnology, a change in Climate?
Dr Peter Reinisch, Partner, Global Life Science Ventures
17.15-18.00
Global Investor Roundtable
Chair: Stan Yakatan, Chairman, Katan Associates
Panelists:
Dr Brian Hargreaves, Global Sector Head – Healthcare, 3i Group
Dr Hervé de Kergrohen, Partner, CDC IXIS Innovation
Antoine Papiernik, Managing Partner, Sofinnova
Dr Yvonne Wegmann, Vice President, Head of Issuers & Investor Relations, SWX Swiss Exchange
Nick Lowcock, Managing Director, Warburg Pincus
18.10
Cocktail Reception
Day Two: Wednesday 5 October 2005
08.00
Registration
09.00-09.15
Opening Welcome:
Reviving the Biotech Industry
Domenico Alexakis, Executive Director, Swiss Biotech Association
9.15-10.00
Alliance Management: Avoiding the Pitfalls.
Strategic and Operational Best Practice Partnerships
Chair: Anthony Rosenberg, Global Head Business Development & Licensing, Novartis Pharma
Panellists:
Dr Arnoud Dijkstra, Director Business Development, Actelion Pharmaceuticals
Michael Levy, Vice President, Alliance Management, Bristol Myers Squibb
Dr Frank Grams, Global Alliance Director, F. Hoffman-La Roche Ltd
Guy Eiferman, Vice President, Alliance Management, Merck & Co
10.00-10.50
Pharma – Biotech M&A; The interface between Big Pharma and Biotech on making a deal and the role investors play
Chair: Dimitri Dimitriou, M.Sc, Chief Executive Officer, DyoDelta Biosciences Ltd
Panellists:
Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse First Boston
Dr Giancarlo Mennella, Managing Director, Egamid
Sandrine Cailleteau, Head, Business Development & Licensing, Laboratoires Fournier
Dr Carles Domenech, Director, Business Developments, Lacer
Dr Peter Johann, Managing General Partner, NGN Capital
10.50-11.20
Coffee Break
11.20-13.10
Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies
11.20
ROOM ZURICH:
IMMUNOLOGY/ONCOLOGY
Chair: Dr Peter Kalinka,
Accelsiors Group		 ROOM BASEL:
THERAPEUTICS
Chair: Emma Palmer,
Northbank Communications		 ROOM BERN:
THERAPEUTICS
Chair: Dr Morris Berrie,
TechInvest
11.25
Intercell
Alexander von Gabain,
Chief Executive Officer		 Archemix
Dr Errol De Souza,
President & CEO 		Artimplant
Tord Lendau,
Chief Executive Officer
11.40
BioVex
Dr Gareth Beynon,
Chief Executive Officer 		Scil Technology
Dr Irina Staatz-Granzer,
Managing Director		 IntegraGen
Dr Jan Mous,
President & CEO
11.55
BOREAN PHARMA
Dr Johanna Holldack,
Chief Executive Officer		 mondoBIOTECH
Dr Dorian Bevec,
Chief Scientific Officer 		Xantos Biomedicine
Stephan Wehselau,
Chief Executive Officer
12.10
mtm laboratories
Dr Peter Pack,
Founding member & CEO 		Santhera Pharmaceuticals
Barbara Heller,
Chief Financial Officer 		Biobase
Michael Tysiak,
Chief Executive Officer
12.25
Diatos
Dr John Tchelingerian,
President & CEO 		Amsterdam Molecular Therapeutics
Prof. Sander van Deventer,
Chief Scientific Officer &
Dr. Ronald Lorijn,
Chief Executive Officer		 Sidec Technologies
Hans Johansson,
Chief Executive Officer
12.40
Nuevolution
Alex Haahr Gouliaev,
Chief Executive Officer		 BioXell
Dr Francisco Sinigaglia,
Chief Executive Officer		 SweTree Technologies
Mats Johnson,
Chief Executive Officer
12.55
Merrimack Pharmaceuticals
Robert Mulroy,
President & CEO		 PAD Pharma
Stuart Wilson,
Scientific Director		 MNLpharma
Haydn Parry,
Chief Executive Officer
13.15
Lunch
14.15-15.00
2006 and Beyond. Innovation and Investment in Medical Devices and Healthcare Technology in Switzerland
Chair: Christof Lenz, Siemens Medical Solutions
Panelists:
Stephen Meier, Partner, BB Medtech
Heinrich Christen, Partner, Ernst & Young
Dr Tom Geimer, Partner, Heidelberg Innovation
Christopher Meyer, Head of Business Development and Strategic Planning, Medtronic Europe
15.10
Close of Conference
 

To download a pdf version of this agenda click here.

Back to top